Free Trial

Faisal Khurshid Analyst Performance

Analyst at Leerink Partners

Faisal Khurshid is a stock analyst at Leerink Partners in the medical sector, covering 11 publicly traded companies. Over the past year, Faisal Khurshid has issued 10 stock ratings, including buy and hold recommendations. While full access to Faisal Khurshid's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Faisal Khurshid's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 2 Years
Buy Recommendations
75.00% 9 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%9 ratings
Hold25.0%3 ratings
Sell0.0%0 ratings

Out of 12 total stock ratings issued by Faisal Khurshid at Leerink Partners, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
11 companies

Faisal Khurshid, an analyst at Leerink Partners, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
11 companies
100.0%

Faisal Khurshid of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
72.7%
MED - DRUGS
1 company
9.1%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
9.1%
PHARMACEUTICAL PREPARATIONS
1 company
9.1%

Faisal Khurshid's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
9/12/2025Initiated Coverage$59.68$73.00Outperform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
8/14/2025Lower Price Target$0.86$2.00Outperform
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
7/7/2025Initiated Coverage$65.78$88.00Outperform
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
7/7/2025Initiated Coverage$3.81$5.00Outperform
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4/14/2025Lower Price Target$0.67$1.00Market Perform
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
4/8/2025Initiated Coverage$12.39$45.00Outperform
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
3/17/2025Initiated Coverage$13.59$16.00Market Perform
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3/17/2025Initiated Coverage$1.19$4.00Outperform
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
3/3/2025Downgrade$1.66$2.00Market Perform
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2/18/2025Initiated Coverage$3.41$16.00Outperform